APIM Therapeutics announced today that the phase 1 data of APIM's lead compound ATX-101 have been published in Oncogene. The data confirm that PCNA is an interesting target for the treatment of cancer. ATX-101 can be administered safely and shows clinical activity. Phase 2 studies are ongoing to demonstrate proof of concept. For more information, please follow this link.
